KR20220140732A - 유비퀴틴-특이적-프로세싱 프로테아제 1(usp1) 억제제 및 폴리 (adp-리보스) 중합효소(parp) 억제제를 포함하는 치료학적 조합물 - Google Patents

유비퀴틴-특이적-프로세싱 프로테아제 1(usp1) 억제제 및 폴리 (adp-리보스) 중합효소(parp) 억제제를 포함하는 치료학적 조합물 Download PDF

Info

Publication number
KR20220140732A
KR20220140732A KR1020227027461A KR20227027461A KR20220140732A KR 20220140732 A KR20220140732 A KR 20220140732A KR 1020227027461 A KR1020227027461 A KR 1020227027461A KR 20227027461 A KR20227027461 A KR 20227027461A KR 20220140732 A KR20220140732 A KR 20220140732A
Authority
KR
South Korea
Prior art keywords
cancer
inhibitor
usp1
parp
rad51
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227027461A
Other languages
English (en)
Korean (ko)
Inventor
앤드류 알리스테어 와일리
솔로몬 마틴 쉔커
파멜라 진 설리번
프랑크 스테그마이어
앤 루이스 캐드조
한란 리우
커스틴 울프 신케비치우스
Original Assignee
케이에스큐 세러퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케이에스큐 세러퓨틱스 인코포레이티드 filed Critical 케이에스큐 세러퓨틱스 인코포레이티드
Publication of KR20220140732A publication Critical patent/KR20220140732A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020227027461A 2020-02-14 2021-02-12 유비퀴틴-특이적-프로세싱 프로테아제 1(usp1) 억제제 및 폴리 (adp-리보스) 중합효소(parp) 억제제를 포함하는 치료학적 조합물 Pending KR20220140732A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062976864P 2020-02-14 2020-02-14
US62/976,864 2020-02-14
US202063032245P 2020-05-29 2020-05-29
US63/032,245 2020-05-29
US202163146937P 2021-02-08 2021-02-08
US63/146,937 2021-02-08
PCT/US2021/017912 WO2021163530A1 (en) 2020-02-14 2021-02-12 Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors

Publications (1)

Publication Number Publication Date
KR20220140732A true KR20220140732A (ko) 2022-10-18

Family

ID=77291879

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227027461A Pending KR20220140732A (ko) 2020-02-14 2021-02-12 유비퀴틴-특이적-프로세싱 프로테아제 1(usp1) 억제제 및 폴리 (adp-리보스) 중합효소(parp) 억제제를 포함하는 치료학적 조합물

Country Status (11)

Country Link
US (1) US20230277533A1 (https=)
EP (1) EP4103165A4 (https=)
JP (1) JP2023514568A (https=)
KR (1) KR20220140732A (https=)
CN (1) CN115066235A (https=)
AU (1) AU2021218805A1 (https=)
CA (1) CA3168009A1 (https=)
IL (1) IL295149A (https=)
MX (1) MX2022009818A (https=)
TW (1) TW202140026A (https=)
WO (1) WO2021163530A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024258235A1 (ko) * 2023-06-16 2024-12-19 한국과학기술연구원 Brca 특이적 sirna를 유효성분으로 포함하는 표적 암 예방 또는 치료용 약학적 조성물

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163530A1 (en) * 2020-02-14 2021-08-19 KSQ Therapeutics, Inc. Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors
KR20230098186A (ko) 2020-10-30 2023-07-03 케이에스큐 세러퓨틱스 인코포레이티드 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도
US20240409538A1 (en) * 2021-10-19 2024-12-12 Impact Therapeutics (Shanghai), Inc. Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof
IL312642A (en) * 2021-11-12 2024-07-01 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
EP4430049A4 (en) * 2021-11-12 2025-12-17 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof
US20250161306A1 (en) * 2022-01-25 2025-05-22 KSQ Therapeutics, Inc. Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumors
JP2025531133A (ja) * 2022-09-20 2025-09-19 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド ユビキチン特異的プロテアーゼ阻害剤としてのカルボニル縮合複素環誘導体
CA3268518A1 (en) * 2022-09-23 2024-03-28 KSQ Therapeutics, Inc. THERAPEUTIC COMBINATIONS INCLUDING UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS (USP1) AND SELECTIVE PARP1 INHIBITORS
CN117384187B (zh) * 2022-09-30 2026-01-30 轩竹生物科技股份有限公司 泛素特异性蛋白酶1抑制剂
EP4605391A1 (en) 2022-10-21 2025-08-27 Exelixis, Inc. 4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
TW202509030A (zh) 2023-05-08 2025-03-01 美商譚格醫療公司 化合物及使用方法
WO2024233665A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
WO2025010245A1 (en) 2023-07-06 2025-01-09 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025087460A1 (zh) * 2023-10-25 2025-05-01 海思科医药集团股份有限公司 一种吡啶并吡唑衍生物药物组合物及其应用
WO2025102016A1 (en) 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
TW202539659A (zh) 2024-01-10 2025-10-16 美商維瑞斯治療股份有限公司 Ｄｎａ損傷修復途徑的新穎抑制劑
WO2025153067A1 (zh) * 2024-01-19 2025-07-24 江苏亚虹医药科技股份有限公司 Usp1抑制剂及其医药用途
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025180502A1 (zh) * 2024-03-01 2025-09-04 上海齐鲁制药研究中心有限公司 一种联合用药物组合物及其用途
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2797719C (en) * 2010-04-30 2019-11-26 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of usp1 deubiquitinating enzyme activity
GB201519573D0 (en) * 2015-11-05 2015-12-23 King S College London Combination
WO2018165615A1 (en) * 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
KR20190130625A (ko) * 2017-03-27 2019-11-22 테사로, 인코포레이티드 니라파립 제제
US11485736B2 (en) * 2018-12-20 2022-11-01 KSQ Therapeutics, Inc. Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors
US20230065636A1 (en) * 2020-01-15 2023-03-02 KSQ Therapeutics, Inc. Compositions of substituted pyrazolopyrimidines and uses thereof
WO2021163530A1 (en) * 2020-02-14 2021-08-19 KSQ Therapeutics, Inc. Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors
KR20230098186A (ko) * 2020-10-30 2023-07-03 케이에스큐 세러퓨틱스 인코포레이티드 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024258235A1 (ko) * 2023-06-16 2024-12-19 한국과학기술연구원 Brca 특이적 sirna를 유효성분으로 포함하는 표적 암 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
IL295149A (en) 2022-09-01
US20230277533A1 (en) 2023-09-07
MX2022009818A (es) 2022-09-05
EP4103165A4 (en) 2024-02-28
TW202140026A (zh) 2021-11-01
CN115066235A (zh) 2022-09-16
WO2021163530A1 (en) 2021-08-19
EP4103165A1 (en) 2022-12-21
AU2021218805A1 (en) 2022-09-01
JP2023514568A (ja) 2023-04-06
CA3168009A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
KR20220140732A (ko) 유비퀴틴-특이적-프로세싱 프로테아제 1(usp1) 억제제 및 폴리 (adp-리보스) 중합효소(parp) 억제제를 포함하는 치료학적 조합물
Smith et al. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy
Tartarone et al. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib
JP6911019B2 (ja) Ｅｇｆｒ−ｔｋｉ耐性を獲得した肺癌の治療薬
DK2704713T3 (en) CSF-1R inhibitors for the treatment of brain tumors
EP2640384A1 (en) Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
US20190055563A1 (en) Polymerase q as a target in hr-deficient cancers
KR20250004723A (ko) 유비퀴틴-특이적-프로세싱 프로테아제 1 (usp1) 억제제 및 화학요법제를 포함하는 치료적 병용물
Meng et al. BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway
KR20250091332A (ko) 유비퀴틴-특이적 처리 프로테아제 1 (usp1) 억제제 및 parp1-선택적 억제제를 포함하는 치료적 조합물
EP2077842A2 (en) Use of an egfr antagonist for the treatment of glomerolonephritis
EA048213B1 (ru) Терапевтические комбинации, содержащие ингибиторы убиквитин-специфической протеазы 1 (usp1) и ингибиторы поли(адф-рибоза)полимеразы (parp)
WO2022226402A1 (en) Inhibitors of ubiquitin specific peptidase 22 (usp22) and uses thereof for treating diseases and disorders
JP2020114857A (ja) Ｒａｆ阻害剤及びタキサンの組み合わせ
HK40120637A (zh) 包含泛素特异性加工蛋白酶1(usp1)抑制剂和parp1-选择性抑制剂的治疗组合
CN118252834B (zh) 维拉佐酮与瑞戈非尼联合用药在治疗结直肠癌中的应用
WO2024088193A1 (en) Combination of aurora a and parp inhibitors for treatment of cancers
US20250339520A1 (en) Compositions and methods for use in kras-targeted therapies for the treatment of cancer
Tumbrink 3.3 MIZ1-∆ POZ shapes treatment response in small cell lung cancer
CN120456904A (zh) 用于治疗胶质母细胞瘤的组合治疗
Nitschmann Anti-neoplastic Activity of Topoisomerase I Inhibitor Etirinotecan Pegol (NKTR-102) and PARP Inhibitor Rucaparib (CO-388) Against Ovarian Cancer Patient Derived Xenograft Models
AU2012250574B8 (en) CSF-1R inhibitors for treatment of brain tumors
Kulasekararaj et al. The Non-transplant Treatment of Myelodysplastic Syndromes—What's on the Horizon?
Bironzo et al. , Achievements in Targeted Therapies-ERS Monographs-Lung Cancer
Tomcik JAK2 as a novel mediator of the pro-fibrotic effects of TGFβ in systemic sclerosis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902